Stockscreener 앱 받기
23.88
6.76%
-1.73
시간 외 거래:
24.01
0.13
+0.54%
전일 마감가:
$25.61
열려 있는:
$25.08
하루 거래량:
408.24K
Relative Volume:
0.73
시가총액:
$752.80M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.35%
1개월 성능:
+29.22%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$23.88
$25.73
1주일 범위
$23.88
$30.05
52주 변동 폭
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.88 | 807.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune (NYSE:EVMN) Trading Down 10.2%Time to Sell? - MarketBeat
Evommune (EVMN) Price Target Increased by 37.87% to 55.08 - Nasdaq
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL) - The Globe and Mail
Evommune (NYSE:EVMN) Trading Down 7.4%Time to Sell? - MarketBeat
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight - openPR.com
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - MSN
Evommune announces $125 million private placement - The Pharma Letter
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Finviz
Benzinga Stock Whisper Index Analysis - Intellectia AI
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Canada
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement - Yahoo Finance
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpHere's Why - MarketBeat
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Evommune Inc on Feb 12, enters securities purchase agreement with investors - marketscreener.com
Evommune Announces $125 Million Private Placement Financing - TipRanks
Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors - TradingView
Evommune Signs Multiple Material Agreements - TradingView
Evommune raises $125M privately - MSN
Evommune raises $125 million in private placement to fund R&D - Investing.com Australia
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune Secures $125M in Private Placement Agreement - Intellectia AI
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com Nigeria
Evommune Enters Private Placement Agreement for $125 Million - Intellectia AI
Evommune Announces $125 Million Private Placement - Business Wire
Evommune Inc (EVMN-N) Insider Trade Summaries - The Globe and Mail
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Bitget
Evommune (EVMN) Valuation Check After Positive Phase 2a EVO301 Results In Atopic Dermatitis - simplywall.st
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - BioPharma Dive
Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge (NYSE:EVMN) - Seeking Alpha
Evommune’s stock rallies 70% on Phase IIa eczema data - Yahoo Finance
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Evommune stock price slips premarket after 71% jump on eczema drug data - Bez Kabli
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial By Investing.com - Investing.com South Africa
Evommune stock soars after positive Phase 2a trial results for eczema drug - Investing.com
Evommune soars on mid-stage atopic dermatitis data - FirstWord Pharma
Evommune, Nektar assets join list of recent successes in atopic derm - BioCentury
H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026 - Meyka
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Evommune Inc (EVMN) 재무 분석
Evommune Inc (EVMN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.71%
0.02%
자본화:
|
볼륨(24시간):